Human Microbiome Drugs Market

The human microbiome drugs market is projected to reach USD 2.13 billion by 2031 from USD 0.35 billion in 2025, at a CAGR of 35.2% during the forecast period.

To know about the assumptions considered for the study download the pdf brochure

Players such as Infant Bacterial Therapeutics AB (Sweden), Ferring B.V. (Switzerland), Seres Therapeutics (US), MaaT Pharma (France), BiomeBank (Australia), and Seed Health, Inc. (US) are emerging as key players in the human microbiome drugs market.

By making strategic moves, such as agreements, product launches, acquisitions, collaborations, and expansions, companies have established a strong market position. In April 2023, the US FDA approved Seres Therapeutics' VOWST (live BCPK), the first fecal microbiota transplant product intended for oral administration.

Seres Therapeutics (US) develops microbiome-based therapies for gastrointestinal and infectious diseases. These therapies are designed using live biotherapeutic products (LBPs) and proprietary microbial consortia. The company conducts research, development, and manufacturing activities, including strain selection, formulation, preclinical testing, and clinical manufacturing. Partnerships with CDMOs and the academic community, coupled with a robust regulatory strategy, facilitate the transition from research to patient studies. Through its dedication to scientific innovation, clinical validation, and precision microbiome intervention, Seres is recognized as a prominent player in the field of microbiome therapeutics.

Ferring B.V. (Switzerland) develops therapies for the digestive tract, reproductive system, and inflammatory diseases. It is also engaged in creating live biotherapeutic products and next-generation microbiome therapies, providing strain optimization, formulation, clinical evaluation, and manufacturing for the supply chain. Ferring has an extensive clinical network and is well-versed in regulatory matters, enabling the company to bring microbiome-based drugs to market rapidly. Its position as a leading player in human microbiome therapeutics is further secured by the company's strategic R&D investments and collaborations.

MaaT Pharma (France): MaaT Pharma is a biotech company that specializes in the development of next-generation, microbiome-based therapies for the treatment of various diseases, particularly in gastroenterology and oncology. The company is developing allogeneic, microbiome-based therapeutics from complex microbial consortia. There is an in-house capability for strain selection, formulation accuracy, GMP-compliant manufacturing, and development of clinical-grade products. Due to collaborations with academic institutions and CDMOs, and the clinical pipeline that is growing, the company can accomplish the seamless and rapid transition from preclinical studies all the way to clinical trials.

Market Ranking

The?‍?‌‍?‍‌?‍?‌‍?‍‌ Human Microbiome Drugs Market is experiencing a moderate consolidation, with the limited approvals for microbiome drugs. The three leading players are Seres Therapeutics (US), Ferring B.V. (Switzerland), and MaaT Pharma (France). Seres is leading the way in the development of live biotherapeutic products (LBPs) by using proprietary microbial consortia and establishing strategic collaborations. Ferring combines formulation, clinical evaluation, and regulatory expertise for the treatment of gastrointestinal tract and inflammatory diseases. MaaT Pharma is the developer of next-generation allogeneic microbiome therapeutics, with an exact formulation and GMP-compliant production. The up-and-coming Biotech companies are introducing innovations through new microbial therapies and delivery methods, which in turn allow them to grow and become more competitive.

Related Reports:

Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com